Researchers develop 3-in-1 vaccine against traveller's diarrhea

October 10, 2018, University of Guelph
University of Guelph researcher develops 3-in-1 vaccine against traveller's diarrhea
Professor Mario Monteiro. Credit: University of Guelph

A first-ever vaccine designed to deliver a one-two-three punch against the main causes of traveller's diarrhea worldwide may result from new research published by a University of Guelph chemist.

Prof. Mario Monteiro says his novel three-in-one approach to developing a new vaccine could also save lives in developing countries, where it's estimated that these three common pathogens kill more than 100,000 children under age five each year.

His research was recently published in the journal Vaccine.

The paper discusses Monteiro's so-called conjugate vaccine that yokes together proteins from pathogenic E. coli with sugars from Shigella and Campylobacter jejuni. All three bugs are major causes of bacterial diarrhea globally.

In tests with mice, the vaccine provided immunity against all three pathogens.

No licensed vaccines exist against any of these pathogens. A sugar-based vaccine developed by Monteiro in 2009 against campylobacter alone is currently undergoing human trials but is still an estimated decade away from potential release.

He said this new three-in-one approach may ultimately overtake that earlier single-target vaccine, although any new vaccine may take decades to test and release. "We're targeting three at the same time," he said. "Instead of three shots, maybe you only need one."

As with the earlier vaccine, this new method has been patented by U of G and the United States Naval Medical Research Center, which funded the research.

Monteiro said further research is needed to determine the optimum amounts of protein and sugars in the vaccine and to make the more efficient.

He worked on the project with former post-doc Zuchao Ma and former graduate students Brittany Pequegnat and Eman Omari, along with U.S. navy researchers.

Explore further: Scientists develop first vaccine to help control autism symptoms

More information: Renee M. Laird et al, Evaluation of a conjugate vaccine platform against enterotoxigenic Escherichia coli (ETEC), Campylobacter jejuni and Shigella, Vaccine (2018). DOI: 10.1016/j.vaccine.2018.09.052

Related Stories

Scientists develop first vaccine to help control autism symptoms

April 24, 2013
A first-ever vaccine created by University of Guelph researchers for gut bacteria common in autistic children may also help control some autism symptoms. The groundbreaking study by Brittany Pequegnat and Guelph chemistry ...

Sugar helping map new ground against deadly bug

April 19, 2011
A potential vaccine against bacteria that cause serious gastric disorders including stomach cancer may be a step closer following a pioneering study by a University of Guelph chemist.

Analysis finds HPV vaccine safe

September 19, 2018
Infection with human papillomavirus (HPV) can cause certain cancers in women and men, but HPV vaccines are highly effective in preventing infection with oncogenic HPV types. A new British Journal of Clinical Pharmacology ...

Team develops a universal vaccine platform that's cheaper and shelf stable

October 5, 2018
Researchers at The University of Texas Medical Branch at Galveston have developed less expensive way to produce vaccines that cuts the costs of vaccine production and storage by up to 80 percent without decreasing safety ...

Sanofi: No proof that vaccine linked to Philippines deaths

February 7, 2018
Drugmaker Sanofi insists there's no evidence of a link between the world's first dengue vaccine and children's deaths in the Philippines.

Live attenuated flu vaccine not effective for children in 2015-16

August 10, 2017
(HealthDay)—During the 2015 to 2016 season, influenza vaccines reduced the risk of influenza illness, but the live attenuated vaccine was ineffective among children 2 to 17 years of age, according to a study published in ...

Recommended for you

Study identifies a key cellular mechanism that triggers pneumonia in humans

December 11, 2018
The relationship between influenza and pneumonia has long been observed by health workers. Its genetic and cellular mechanisms have now been investigated in depth by scientists in a study involving volunteers and conducted ...

Human antibody discovery could save lives from fungal killer

December 11, 2018
A new way to diagnose, treat and protect against stealth fungal infections that claim more than 1.5 million lives per year worldwide has been moved a step closer, according to research published in Nature Communications.

Effect of oral alfacalcidol on clinical outcomes in patients without secondary hyperparathyroidism

December 11, 2018
Treatment with active vitamin D did not decrease cardiovascular events in kidney patients undergoing hemodialysis, according to a research group in Japan. They have reported their research results in the December 11 issue ...

Dialysis patients at risk of progressive brain injury

December 10, 2018
Kidney dialysis can cause short-term 'cerebral stunning' and may be associated with progressive brain injury in those who receive the treatment for many years. For many patients with kidney failure awaiting a kidney transplant ...

Silicosis is on the rise, but is there a therapeutic target?

December 6, 2018
Researchers from the CNRS, the University of Orléans, and the company Artimmune, in collaboration with Turkish clinicians from Atatürk University, have identified a key mechanism of lung inflammation induced by silica exposure, ...

PET scans to optimize tuberculosis meningitis treatments and personalize care, study finds

December 6, 2018
Although relatively rare in the United States, and accounting for fewer than 5 percent of tuberculosis cases worldwide, TB of the brain—or tuberculosis meningitis (TBM)—is often deadly, always hard to treat, and a particular ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.